publication date: Aug. 3, 2010
In this issue: Taking Profit Out Of ESAs, Insurer Sending Controversial Drugs Directly To Patients. ODAC Votes Against Cell Therapeutics Agent; Requires ChemGenex To Develop Diagnostic. Report Urges Changes To Cut Activation Times For NCI Phase III Trials. AACR Elects Officers. Download PDF
To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.